source
- ADARx aims for $318 million IPO as TRexBio and Retension also fileADARx Pharmaceuticals, a siRNA biotech currently in Phase 3 trials, announced plans to raise roughly $318 million through an initial public offering. The company is joining other biotech firms suc…
- Par Health recalls two lots of dexmedetomidine infusion due to particulate contaminationPar Health announced a voluntary recall of two lots of its dexmedetomidine HCl in 0.9% sodium chloride injection, which is used for intravenous sedation. The recall was initiated after testing ide…